德适生物港股IPO获证监会备案 客户已覆盖超400家医疗机构

Core Viewpoint - The China Securities Regulatory Commission has approved the overseas listing of Hangzhou Deshi Biotechnology Co., Ltd., allowing the company to issue up to 31.04 million shares for listing on the Hong Kong Stock Exchange, while 27 shareholders will convert a total of 80.88 million domestic unlisted shares into overseas listed shares [1] Group 1: Company Overview - Deshi Biotechnology is a leading enterprise in the field of medical imaging AI and medical imaging equipment, with a global market presence [1] - The company has developed a diversified product matrix based on its self-developed general medical imaging base model, iMedImage, including systems for chromosome karyotype analysis and automatic cell imaging [1] - In 2024, Deshi Biotechnology achieved a market share of 30.6% in China's chromosome karyotype analysis sector, ranking first and breaking the long-standing monopoly of imported brands [1] Group 2: Market Position and Recognition - The company has established a customer base covering over 400 medical care centers and institutions across China, gaining widespread market recognition [1] - In 2025, Deshi Biotechnology was selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog" due to its technological innovation and clinical value [1] Group 3: Future Plans - The company plans to continue providing standardized intelligent imaging equipment, a Model-as-a-Service (MaaS) cloud platform, and localized self-training solutions to enhance the efficiency, accuracy, and accessibility of medical imaging diagnostics [2] - Deshi Biotechnology aims to lead the global medical imaging industry into an era of intelligence through technological innovation [2]